Glecaprevir + Pibrentasvir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Glecaprevir- 100 mg + Pibrentasvir - 40 mg
Reference Brands: Mavyret (US); Maviret (EU)
Category:
Anti Viral
Mavyret/Maviret is a once-daily 3-tablet regimen combining Glecaprevir and Pibrentasvir for pan-genotypic HCV treatment. It offers short 8-week therapy, high cure rates, and is safe for patients with kidney or liver issues.
Glecaprevir + Pibrentasvir is available in Tablet
and strengths such as Glecaprevir- 100 mg + Pibrentasvir - 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Glecaprevir + Pibrentasvir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Glecaprevir + Pibrentasvir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Mavyret (US) / Maviret (EU) is a fixed-dose combination of Glecaprevir 100 mg and Pibrentasvir 40 mg per tablet, approved by the FDA and EMA for the treatment of chronic hepatitis C virus (HCV) infection across genotypes 1–6. This pan-genotypic regimen is taken as three tablets once daily with food. It offers one of the shortest HCV treatments—just 8 weeks for most patients. Mavyret is highly effective (SVR >95%) and suitable for use in patients with renal impairment and compensated cirrhosis. Its ribavirin-free formulation improves tolerability, making it a convenient, high-efficacy option for diverse patient populations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing